Vancouver, Canada – Zymeworks Inc. today announced that it has entered into a collaboration and license agreement with GlaxoSmithKline (GSK) for the research, development, and commercialization of novel Fc-engineered monoclonal and bi-specific antibody therapeutics which have been optimized for specific therapeutic effects. Under the terms of the agreement, Zymeworks and …